Belgium· BE-AMP-SAM567457-00
Piqray 50 mg - 200 mg
A alpelisib product containing alpelisib, registered in Belgium by Novartis Europharm. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Alpelisib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EM03 (alpelisib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Alpelisib · ATC L01EM03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of alpelisib costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alpelisib · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$136.30
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Alpelisib
- Manufacturer
- Novartis Europharm
- Country
- Belgium (BE)
- ATC code
- L01EM03
- ATC class
- Alpelisib
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 1
- be_apb4230074
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
347 interactions on record for alpelisib.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Alpelisib · interactions on record
347 records
- 14 severe
- 329 moderate
- 4 minor
Most severe, free to view
- EdoxabanB01AF03severe
- RifampicinJ04AB02severe
- RifabutinJ04AB04severe
- RifapentineJ04AB05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Alpelisib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenPiqray 50 mg + 200 mg Filmdragerad tablettNovartis Europharm Limited
- NetherlandsPiqray 50 mg filmomhulde tablettenNovartis Europharm Limited
- SpainPIQRAY 50 MG y 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- FinlandVijoiceNovartis Europharm Limited
- FrancePIQRAY 50 mg et 200 mg, comprimé pelliculéNOVARTIS EUROPHARM (IRLANDE)
- NorwayPiqrayNovartis Europharm Limited (1)
- PolandVijoiceNovartis Europharm Limited
- IrelandPiqray 50 mg film-coated tablets Piqray 200 mg film-coated tabletsNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Piqray, Vijoice
- Liechtenstein · Piqray, Vijoice
- Norway · Piqray, Vijoice
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e3cc9f64-a63d-47ac-bbca-5a4298070530 GET /v1/drugs/e3cc9f64-a63d-47ac-bbca-5a4298070530?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Piqray 50 mg - 200 mg",
"name_fr": "Piqray 50 mg - 200 mg",
"name_nl": "Piqray 50 mg - 200 mg",
"amp_code": "SAM567457-00",
"strengths": [
"50.0000",
"200.0000"
],
"pack_count": 3,
"substances": [
"Alpelisib",
"Mannitol",
"Sodium Starch Glycolate"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Alpelisib",
"authorisation_numbers": [
"EU/1/20/1455/004",
"EU/1/20/1455/005",
"EU/1/20/1455/006"
]
}See everything about alpelisib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.